911
Participants
Start Date
July 11, 2022
Primary Completion Date
August 17, 2022
Study Completion Date
September 1, 2022
NVX-Cov2373
Intramuscular (deltoid) injection of SARS-CoV-2 rS co-formulated with Matrix-M adjuvant (0.5 mL) on Day 1
Meridian Clinical Research, Endwell
Rochester Clinical Research, Rochester
OnSite Clinical Solutions, LLC, Charlotte
CRA Headlands, Stockbridge
Cen/Excel ACMR, Atlanta
Meridian Clinical Research, Savannah
Multi-Specialty Research Associates, Inc., Lake City
Jacksonville Center for Clinical Research, Jacksonville
Accel Clinical Research, DeLand
Research Centers of America, Hollywood
MedPharmics, Gulfport
Velocity Clinical Research, Cleveland
CTI Clinical Research Center, Cincinnati
Meridian Clinical Research, Sioux City
Sundance Clinical Research, St Louis
Meridian Clinical Research, Omaha
Meridian Clinical Research, Norfolk
Meridian Clinical Research, Baton Rouge
Tekton Research, Yukon
Lynn Health Science Institute, Oklahoma City
Research Your Health, Plano
Benchmark Research, Houston
Tekton Research, San Antonio
Benchmark Research, Austin
Tekton Research, Austin
Velocity Clinical Research, Boise
Long Beach Clinical Trial Services Inc., Long Beach
Benchmark Research, Sacramento
Velocity Clinical Research, Grants Pass
Velocity Clinical Research, East Greenwich
Lead Sponsor
Novavax
INDUSTRY